Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism

Fig. 4

Multiple comparison tests at 25 weeks confirm positive prognosis to rGBM patients harboring the TT polymorphic variant of MTHFR rs1801133 in comparison to the remaining variants, both for patients with lower survival times (TT = 18 weeks; CC = 8 weeks; d = 1.583 and CT = 12 weeks, d = 0.941), as well as for those who achieved higher survival times (TT = 92 weeks; CC = 44 weeks; d = 0.648 and CT = 48 weeks, d = 0.807). Besides, significant prognosis differences were also observed within and between such MTHFR variants after and before the specific moment during inhaled POH treatment (Supplementary Table 4)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us